Embed Size (px)
Citation preview
Jennifer Filbey, Ph.D. | CEO | March 2017
Mazen Animal Health
Revolutionary Way to Prevent Disease and Save the
Producer Money
2
The Strategic Opportunity
3
NOVEL VACCINE production platform in maize
enables oral administration
At a lower cost than
current practices
Oral Vaccines Benefit both Animal and Animal
Producer
4
Reduces animal handling
Reduces animal stress
No injection site issues
In line with current farming
practices
• Lactogenic immunity for neonatal diarrheas: Porcine
Epidemic Diarrhea Virus (PEDv), E.Coli, ...
• Porcine Reproductive & Respiratory Syndrome (PRRS)
First Target Oral Swine Vaccines
• Characterized by diarrhea, causing dehydration and high mortality
• Losses cost industry hundreds of millions annually
• Lactogenic immunity can have high impact on prevention
5
Neonate Diarrhea
• Presents as reproductive failures and post weaning respiratory diseases
• No effective treatments for acute PRRS
• Over $600M in losses annually
PRRS
Combination vaccination possible
Rationale for Swine Vaccines:
• Unmet need for effective vaccines
• 2nd largest animal vaccine market
• Proof of concept in swine
Protection Against TGEV in Piglets DemonstratedOral vaccine shows protection comparable to modified live virus vaccine
Response of oral
vaccinated piglets to
viral challenge on Day
18 was significantly
improved (p<0.001)
over control and similar
to commercial vaccine
B.J. Lamphear, S.J. Streatfield, J.M.Jilka,C.A. Brooks, D.. Barker, D.D. Turner, D.E. Delaney, M.Garcia,
B. Wiggins, S.L. Woodard, E.E. Hood, I.R. Tizard, B. Lawhorn, J. A Howard J. Control. Release (2002) 85:169-180.
*Clinical Severity Index = total clinical score values
divided by the total number of pig days
6
00.05
0.10.15
0.20.25
0.30.35
0.4
control corn,16 days
TGEV corn, 4days
MLV TGEV
Clinical Severity Index*
Control Oral MLV
VP2 & VP3
Infectious Pancreatic
Necrosis Virus (IPNV)
F PROTEIN
Newcastle Disease
Virus (NDV)
Proof of Concept for Oral Vaccination has been
Demonstrated in Several Species
G PROTEIN
Rabies
S PROTEIN
Transmissible
Gastroenteritis
Virus (TGEV)
7
Addressable Market for Mazen’s Vaccine Platform is Large
WW:$630M
US: $185M
13% AGR
WW:$1.3B
US: $370M
9% AGR
Mazen’s Initial Focus Is Oral Swine Vaccines
WW:$2.1B
US: $710M
8% AGR
WW:$1.5B
US: $520M
11% AGR
WW:$15M
US: $10M
15% AGR
Current Vaccine Products Dominated by InjectablesWith topical and water-based vaccines entering the poultry market
9
$0.0
$1.0
$2.0
$3.0
$4.0
$5.0
$6.0
$7.0
$8.0
Current Vaccines Mazen Solution
PEDV
The Mazen Solution Saves the Producer 50% in Cost to
Vaccinate Compared to Competition
10
Mazen oral vaccines, at 25% less dose-for-dose, save the producer 50% in the total cost of vaccination
Margin
Cold chain shipment
Failure to immunize premium
Cost to inject
Vaccine
• Competition is current
injectable vaccines
• Oral vaccine platform
offers significant
advantages over
injectable vaccination
• High barriers to entry
A Paradigm Shift in Vaccination Provides Significant Market
Opportunity
Assumes a 30% market share
Assumes selling price is lower than the injected vaccine
Value of lower cost for administration is shared with end user
11
53 acres
32 acres
$0
$20,000,000
$40,000,000
$60,000,000
$80,000,000
$100,000,000
$120,000,000
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
PRRS (gross)
PEDV gross)
Mazen is leveraging technology developed at ABI with an
exclusive license in animal health
12
IgG & IgA
response after
oral
administration
Issued & pending
patents with
extensive know-
how
USDA inspected
manufacturing
facilities
USDA Oversees Vaccines in Animal HealthProduction of Antigen Regulated by APHIS &
Production/Testing/Sale of Vaccine Regulated by CVB
Animal & Plant Health
Inspection Service
Center for
Veterinary Biologics
Purity,
Potency,
Safety,
Efficacy
13
14
MAZEN WILL
DEVELOP
& COMMERCIALIZE
ORAL VACCINES
14
Strong Team Leadership to Implement Strategy
15
JENNY FILBEYPh.D., CEO
• Experienced executive in start-up biotech and large pharmaceutical co’s
• Strong background ranging from research to capital raising—
bridging the science and the business
• Founded New Perspectives, directing virtual commercial strategy and operations
teams
• Focus on transforming the strategic direction to enhance value for companies
• Leader in business strategy & partnerships initiatives
• Background spans early-stage start-up to Fortune 200 companies
• Experienced across multiple key market sectors: vaccines, animal
health, consumer products
• Skilled relationship management in corporate, government and NGO
partnershipsVICKI MORGAN
MBA, Market & Business Development
Strong Team Leadership to Implement Strategy
• World-leading expert in protein expression in maize
• 30+ years directing research, regulatory, & production facilities of plant
biotechnology products in pharmaceutical and industrial settings
• Demonstrated oral vaccination from maize in swine and other
livestock species
• Leads commercial production facility for proteins from maize system
16
JOHN HOWARDPh.D., Chairman
CELINE HAYDENPh.D., Research & Development
• PhD & NIH IRACDA Fellow in Plant Molecular Genetics
• Experienced plant biotechnology & oral vaccine R&D
• Directed all aspects of research, preclinical studies, regulatory
compliance, and product development for oral vaccine candidates
• Leads vaccine product development
Mazen is supported by an experienced group of advisors
17
Ronan MolloyInnovation Stockyard
Tom OverbayExpedite
Dennis SteadmanSteadman Consulting
Kelly LechtenbergMVS / CSRC
Randal ChaseAdvanced Proteome Therapeutics
Terry SpeizerAdvisor
Dick HesseK-State Advisor
Series A will Fund Safety & Efficacy StudiesCompleted Initial Close of Angel Round - Open up to mid-May
18
Potential exits
M&A Animal Health Co’s Access to public market for commercialization
Mazen will achieve significant milestones
AntigenReg confirmation of development plan
Animal testing Market ResearchStrategic
partnerships
Mazen has budgeted $6-$8M over next two years
Angel round on-going up to $1M Series A round targeted for $5-$7M
Why Invest?
Paradigm ShiftHigh Revenue
Potential
Multiple Exit
Scenarios
De-risked OpportunityExperienced
Team
19
20
www.mazenanimalhealth.com
Jennifer Filbey, Ph.D. | CEO
+1-256-417-8568
Vicki Morgan | VP, Business & Market Development
+1-919-641-8146
Thank you
“I am fond of pigs.
Dogs look up to us.
Cats look down on us.
Pigs treat us as equals.”-Winston Churchill
